🇺🇸 FDA
Patent

US 11759476

Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors

granted A61KA61K31/7088A61K31/7105

Quick answer

US patent 11759476 (Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/7088, A61K31/7105, A61K31/713, A61K38/22